Table 1 Patient characteristics and outcomes
| Â | Early active RA trials | Established active RA trials | RA remission/LDA studies | |||
|---|---|---|---|---|---|---|
| Â | CARDERA-1 | CARDERA-2 | TITRATE | TACIT | OPTTIRA | REMIRA |
| Â | n = 355 | n = 135 | n = 292 | n = 177 | n = 85 | n = 88 |
Study type | Trial of methotrexate, ciclosporin and steroids | Trial of methotrexate and anakinra | Trial of biologic DMARDs and synthetic DMARDs | Trial of treat to target and routine care | Trial of biologic DMARD tapering | Observational study |
Demographics | ||||||
 Females, n (%) | 241 (68%) | 92 (68%) | 238 (82%) | 137 (77%) | 63 (74%) | 58 (66%) |
 Age (years) | 54 (12) | 55 (12) | 57 (12) | 57 (12) | 57 (11) | 57 (15) |
 Disease duration (years) | 0.3 (0.4) | 0.1 (0.2) | 6 (6) | 8 (9) | 11 (12) | 4 (3) |
Baseline outcome measures | ||||||
 28 TJC | 11.2 (7.5) | 16.9 (7.5) | 7.5 (4.1) | 16.9 (6.7) | 0.4 (0.8) | 0.6 (1.0) |
 28 SJC | 9.6 (6.2) | 11.7 (6.9) | 4.1 (2.7) | 10.6 (6.5) | 0.4 (1.0) | 1.2 (2.0) |
 ESR | 42 (30) | 39 (23) | 16 (14) | 32 (25) | 13 (13) | 11 (9) |
 PtGA | 55 (27) | 58 (28) | 46 (20) | 68 (20) | 10 (11) | 25 (21) |
 DAS28-ESR | 5.8 (1.3) | 6.4 (1.2) | 4.4 (0.5) | 6.3 (0.8) | 1.9 (0.8) | 2.2 (0.9) |
 Pain intensity VAS | 46 (25) | 55 (28) | 42 (22) | 66 (20) | 11 (14) | 23 (25) |
12-month outcome measures | ||||||
 28 TJC | 5.2 (5.6) | 8.6 (9.1) | 5.6 (5.5) | 6.4 (7.6) | 2.1 (3.7) | 0.8 (1.6) |
 28 SJC | 7.1 (7.8) | 4.1 (5.8) | 2.7 (3.5) | 3.3 (4.4) | 1.3 (2.5) | 1.0 (2.2) |
 ESR | 28 (22) | 23 (20) | 16 (16) | 23 (23) | 14 (13) | 12 (11) |
 PtGA | 36 (27) | 33 (28) | 35 (26) | 40 (30) | 18 (20) | 27 (24) |
 DAS28-ESR | 4.3 (1.6) | 4.2 (1.8) | 3.6 (1.4) | 3.9 (1.6) | 2.5 (1.3) | 2.2 (1.1) |
 Pain intensity VAS | 32 (26) | 36 (30) | 33 (28) | 40 (29) | 20 (21) | 26 (26) |